Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
NORTHVALE, N.J., May 04, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today that its Board of Directors has appointed Davis S. Caskey to its board effective April 28, 2016.
Davis Caskey is the newest member of Elite's Board and brings more than 40 years of pharmaceutical industry experience to this position. From 1990 until 2013, Mr. Caskey was employed by ECR Pharmaceuticals Co., Inc. ("ECR"), a venture that was founded in 1990 and acquired by Hi-Tech Pharmacal in March 2009, where he served as the operating officer. Upon leaving ECR, Mr. Caskey formed Caskey LLC, an umbrella company to provide consulting services to the pharmaceutical industry and for the management of other business interests. While at ECR, Mr. Caskey was credited with the establishment of ECR's sales and marketing structure, its product distribution format, and management of the firm's internal organization. His responsibilities included the oversight of drug development and regulatory filings. A primary focus was to conceive and develop, with the assistance of key strategic partners, extended release formulations of products which enhance patient compliance and safety. Prior to ECR, Mr. Caskey was employed by A.H. Robins for 18 years. His experience brings critical insight into the marketing and distribution of pharmaceutical products in a rapid and ever changing competitive marketplace. Mr. Caskey attended the University of Texas (Austin) and Lamar University, and holds bachelor's and master's degrees.
"We are delighted to welcome Davis Caskey to our Board of Directors where his pharmaceutical industry expertise will have an invaluable impact on the success of Elite," stated Nasrat Hakim, Elite's Chairman of the Board. "We look forward to his guidance and expertise as we expand our pharmaceutical operations."
